CHRISTOPHER STONE: Open Payments
NPI 1912473125 · LITTLE ROCK, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$502 in 20 payments from 8 companies in 2025. Trend: 2023 $568 · 2024 $533 · 2025 $502
Food & beverage: $502
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 6 | $170 |
| Lundbeck LLC | 3 | $88 |
| ABBVIE INC. | 4 | $83 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| E.R. Squibb & Sons, L.L.C. | 1 | $26 |
| Tris Pharma Inc | 1 | $21 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
Products named: INGREZZA, REXULTI, VRAYLAR, CAPLYTA, TRINTELLIX, COBENFY, Dyanavel XR, Jornay PM.
Industry payments across AR — which companies pay providers there.
